Original Research

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, Galsky M

ClinicoEconomics and Outcomes Research 2019, 11:659-672

Published Date: 8 November 2019